drugset / Trial / NCT00458250

Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H

NCT00458250

Phase 1 Completed 10 enrolled Tehran University of Medical Sciences
Non-randomizedFactorialOpen-labelTreatment

Summary

Many patients suffering various malignant and non-malignant diseases need hematopoietic stem cell transplantation from a healthy person. In the majority of cases there is no matched related or unrelated donor. Some researchers have been performed transplantation from semi-matched (haploidentical) related donors with relatively good results. Chinese researchers have been performed this kind of transplantation using CAMPATH-1H and their reports indicates good results. Chinese populations have more homogenous genetic background than Iranians. In this project, we are going to study the feasibility of this method of haploidentical transplantation in Iranian patients.

Timeline

Start
2006-09
Primary completion
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody
Background Busulfan Small molecule
Background Cyclophosphamide Other / unclassified
Background Cyclosporine Peptide
Background Methotrexate Small molecule